scholarly article | Q13442814 |
P356 | DOI | 10.1097/CCO.0000000000000107 |
P698 | PubMed publication ID | 25014645 |
P50 | author | Guillaume Cartron | Q38803376 |
Anne-Laure Gagez | Q51749890 | ||
P2093 | author name string | Guillaume Cartron | |
Anne-Laure Gagez | |||
P2860 | cites work | Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity | Q30835165 |
P433 | issue | 5 | |
P921 | main subject | monoclonal antibody | Q422248 |
P304 | page(s) | 484-491 | |
P577 | publication date | 2014-09-01 | |
P1433 | published in | Current Opinion in Oncology | Q1909046 |
P1476 | title | Obinutuzumab: a new class of anti-CD20 monoclonal antibody | |
P478 | volume | 26 |
Q50063710 | Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region |
Q92718871 | CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γc cytokine stimulation via PI3K/mTOR axis |
Q38881164 | Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia |
Q92084382 | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists |
Q38329651 | How to successfully patent therapeutic antibodies |
Q28069362 | Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies |
Q28385366 | Mechanisms of action of therapeutic antibodies for cancer |
Q38759420 | Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy |
Q37741570 | Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production |
Q33780903 | Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas |
Q40088787 | Potent In Vivo NK Cell-mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-bispecific and Hexavalent Broadly Neutralizing Fusion Protein. |
Q64044243 | Recent advances in the management of systemic lupus erythematosus |
Q35040896 | The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis |
Q39018189 | The safety profile of monoclonal antibodies for chronic lymphocytic leukemia |
Search more.